Plain-English translation of NCT06911684 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for locally advanced rectal cancer that hasn't spread. The study combines short-term radiation therapy with a newer immunotherapy drug called QL1706 (which works on the immune system in a dual way), along with two chemotherapy medications. The goal is to see if this combination can help more patients have a complete response to treatment before surgery.
Current standard treatment for advanced rectal cancer helps many patients, but some still experience cancer returning after surgery or have complications. This trial exists to test whether adding newer immunotherapy drugs to radiation and chemotherapy can improve how well the cancer responds before surgery, potentially leading to better long-term outcomes.
You likely qualify if…
You likely don't qualify if…
Depending on which study group you're randomly assigned to, you would receive either two cycles of the medication combination before radiation, then radiation therapy, then four more cycles—or radiation therapy followed by six cycles of the medication. The medications are given intravenously and by mouth over several months. Throughout this time, you'll have regular clinic visits for blood tests, imaging scans, and physical exams. After completing all the therapy, you'll have surgery to remove the cancer, followed by continued monitoring.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China